Cookies

Like most websites The Ophthalmologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subspecialties Retina

The Optogenetic Option

At a Glance

  • Optogenetics, a technique that originated in neuroscience research, allows neuronal activity to be controlled with light – and potentially bypass damaged photoreceptors to help partially restore vision in those with retinal degenerative disease
  • Many of the methods under development are now poised to move to the clinical trial stage, with some prototype manufacturers working towards FDA approval for their devices
  • Subretinal implants, biomimetic goggles and programmable computer chips are among the devices that may soon work with optogenetic methods to restore vision in patients with photoreceptor damage
  • Photoreceptor rejuvenation or regeneration may remain the most direct path to recovering vision, but photopharmacological switches, retinal prostheses and optogenetics continue to evolve

In the battle to restore vision for those with lost or damaged photoreceptors, progress is being made on many fronts. I have previously described the possibility of reversing blindness by regenerating retinal photoreceptors (1). But there is another promising approach – optogenetics. There are a number of universities and companies currently working in this field, and in this article I will attempt to summarize the current state of research and detail how close we are to human trials of optogenetics-based techniques for restoring lost vision.

Read the full article now

Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Author

Irv Arons

Irv Arons’ Journal is a well-read blog that reports on new drugs and devices for the treatment of retinal diseases, including age-related macular degeneration (AMD). Until his retirement, Irv was a consultant to the ophthalmic and medical laser industries, working for management consultants Arthur D. Little for 25 years and running his own company, Spectrum Consulting, for 11 years.

Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register